IXEKIZUMAB in the management of Psoriasis - Pan Mersey APC Skip to main content Help with accessibility Skip to main navigation

IXEKIZUMAB in the management of Psoriasis

Last Updated: 27 June 2018

Body System: Skin

Red

The Pan Mersey Area Prescribing Committee recommends the sequential use of biological agents, adalimumab (Humira®), brodalumab (Kyntheum®▼), etanercept (Benepali®▼, Enbrel®), infliximab (Inflectra®▼, Remicade®, Remsima®▼), ixekizumab (Taltz®▼), secukinumab (Cosentyx®▼) and ustekinumab (Stelara®), in the management of psoriasis according to the attached flowchart.